13 Analysts Have This To Say About Vertex Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the past three months, with a slight increase in the average 12-month price target. The company's financials show strong net margins and return on equity, but its revenue growth lags behind industry peers.
June 17, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vertex Pharmaceuticals has received mixed ratings from analysts, with a slight increase in the average 12-month price target to $455.69. The company's financials show strong net margins and return on equity, but its revenue growth lags behind industry peers.
The mixed analyst ratings and slight increase in the average price target suggest a cautiously optimistic outlook for Vertex Pharmaceuticals. The company's strong net margins and return on equity are positive indicators, but the lagging revenue growth compared to industry peers may temper short-term enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100